SEC Filing Summary: Wound Management Technologies, Inc. (10-Q)
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2012. The registrant is Wound Management Technologies, Inc. (WMT), a smaller reporting company focused on the advanced wound care market. Its primary product is CellerateRX, an activated collagen medical device cleared by the FDA for acute and chronic wounds. The company markets the product to hospitals, wound care centers, and long-term care facilities. Management has initiated a strategic plan to achieve sustained positive cash flow by year-end 2012 through disciplined sales growth.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2012 | Six Months Ended June 30, 2011 (Restated) |
|---|---|---|
| Revenues | $373,946 | $1,163,110 |
| Cost of Goods Sold | $311,947 | $179,153 |
| Gross Profit | $61,999 | $983,957 |
| Net Income (Loss) | $257,855 | $(6,601,274) |
| Cash and Cash Equivalents (End of Period) | $0 | $206,335 |
| Total Assets | $3,162,640 | $3,832,517 |
| Total Liabilities | $5,613,511 | $7,692,532 |
| Stockholders' Equity (Deficit) | $(2,450,871) | $(3,860,015) |
Liquidity Note: The company reported zero cash on hand as of June 30, 2012, with a bank overdraft of $11,913. Net cash used in operating activities was $859,860 for the six-month period.
Material Changes vs. Prior Period
- Revenue Decline: Six-month revenues decreased 68% to $373,946. This decline is primarily due to the absence of a one-time $500,000 revenue receipt in 2011 from the sale of distribution rights to CellerateRX powder. Regular product sales actually increased in 2012.
- Profitability Turnaround: The company reported a net income of $257,855 for the six months ended June 30, 2012, compared to a net loss of $6.6 million in the prior year. This improvement is driven by a significant reduction in debt-related expenses and a $2.67 million gain from the change in fair value of derivative liabilities.
- Expense Reduction: General and administrative expenses dropped 62% to $684,466 due to reduced marketing, consulting, and payroll costs. Interest expense decreased 83% and debt-related expenses decreased 79% as the company utilized equity compensation to secure financing rather than high-interest debt.
- Derivative Liabilities: The fair value of derivative liabilities decreased from $5.42 million to $2.47 million, contributing significantly to the reported net income.
Guidance, Outlook, Risks, and Contingencies
- Going Concern: The filing includes a "Going Concern" warning. The company has current liabilities exceeding current assets and a stockholders' deficit. Continuation as a going concern is dependent on obtaining additional funding and the success of future operations.
- Legal Proceedings:
- SEC Complaint: On June 4, 2012, the SEC filed a complaint against the company and former officer Scott A. Haire alleging a fraudulent scheme and market manipulation involving stock sales and kickbacks. The company is in settlement discussions.
- Tonaquint Lawsuit: On July 13, 2012, Tonaquint, Inc. filed suit regarding a $560,000 secured convertible promissory note, alleging failure to make payments and honor conversion notices.
- Contractual Commitments:
- IRS Liability: The company is negotiating to settle a remaining obligation of approximately $208,142 related to 2004-2005 payroll tax fees and interest.
- Royalties: Unpaid royalties to Applied Nutritionals, LLC totaled $615,738 as of June 30, 2012.
- Outlook: Management expects to launch a new bone wax product by year-end 2012 and is exploring feasibility studies for dental and dermatology markets. A strategic partnership with WellDyne is in place to expand sales to physicians and long-term care facilities.
Investor Verification Checklist
- Cash Position: Verify the company's ability to operate with $0 cash on hand and a bank overdraft.
- Derivative Liability Volatility: Assess the sustainability of net income, which is heavily influenced by non-cash changes in the fair value of derivative liabilities ($2.67M gain).
- Legal Exposure: Monitor the outcome of the SEC complaint regarding market manipulation and the Tonaquint lawsuit regarding debt conversion.
- Debt Settlement: Confirm the status of the $208k IRS obligation and the $615k accrued royalty liability.
- Revenue Quality: Distinguish between the one-time 2011 distribution rights sale and recurring product sales growth.